Press Releases September 2, 2026 08:00 AM

iMDx to Participate in Lake Street 10th Annual Best Ideas Growth “BIG10” Conference

Insight Molecular Diagnostics to Present at Lake Street 10th Annual Best Ideas Growth Conference

By Ajmal Hussain
Share
Twitter Reddit Facebook LinkedIn
IMDX

Insight Molecular Diagnostics Inc. announced its participation in the upcoming Lake Street Capital Markets 10th Annual Best Ideas Growth Conference scheduled for September 10, 2026, where its CEO and CFO will engage in one-on-one investor meetings in New York City.

iMDx to Participate in Lake Street 10th Annual Best Ideas Growth “BIG10” Conference
IMDX
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Insight Molecular Diagnostics is actively engaging with investors through a significant growth-focused conference.
  • Top executives, including CEO Josh Riggs and CFO Andrea James, will represent the company, indicating a strategic push for investor relations.
  • The company's mission focuses on democratizing access to advanced molecular diagnostic testing, targeting improved patient outcomes, highlighting its role in healthcare innovation.

NASHVILLE, Tenn., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced participation in the upcoming Lake Street Capital Markets 10th Annual Best Ideas Growth “BIG10” Conference taking place September 10th, 2026 in New York.

Event: Lake Street Capital Markets 10th Annual Best Ideas Growth “BIG10” Conference
Who: Chief Executive Officer Josh Riggs and Chief Financial Officer Andrea James
Date: Thursday, September 10, 2026
Location: Metropolitan Club, New York City
Format: One-on-one meetings

Investors wishing to meet with IMDX management are encouraged to reach out to their Lake Street sales representative.

About Insight Molecular Diagnostics Inc.
Insight Molecular Diagnostics is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. Investors may visit https://investors.imdxinc.com/ for more information.

GraftAssureCore™, GraftAssureIQ™, GraftAssureDx™, VitaGraft™, GraftAssure™, DetermaIO™, and DetermaCNI™ are trademarks of Insight Molecular Diagnostics Inc.

Investor Contact:
Alexandra Grossman
LifeSci Advisors LLC
[email protected] 


Risks

  • The article does not discuss specific financial results or new product launches, so near-term market impact may be limited.
  • Participation in investor conferences does not guarantee new investments or stock price appreciation, as market reception depends on broader fundamental and sector conditions.
  • The molecular diagnostics and healthcare sectors face competitive pressures and regulatory risks, which might impact company performance despite investor outreach efforts.

More from Press Releases

Zhihu Inc. Announces Proposed Subscription in AI-Focused Investment Fund Sep 6, 2026 Roivant to Present Topline Results from the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) at the ERS Congress 2026 on Tuesday, September 8, 2026, and Host Investor Call Sep 6, 2026 Verizon Waives Charges for Hurricane Lowell, Prepares Network in Hawai'i Sep 5, 2026 Royalty Pharma announces update on Novartis’ Phase 3 topline results for pelacarsen Sep 4, 2026 Grupo Aeroportuario del Pacifico Reports a Passenger Traffic Increase in August 2026 of 0.5% Compared to 2025 Sep 4, 2026